Evidence map›Paper›PMID 42467872›Full record

ReviewNeurology2026

The Promise and Peril of Alzheimer Disease Prevention.

Joshua D Grill, Jonathan Graff-Radford

Abstract readReview
In one paragraph

Review in Neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Joshua D GrillInstitute for Memory Impairments and Neurological Disorders, Departments of Psychiatry and Human Behavior and Neurobiology and Behavior, University of California, Irvine; and.ORCID 0000-0002-4215-7589
Jonathan Graff-RadfordMayo Clinic, Rochester, MN.ORCID 0000-0003-2770-0691

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Interventions to delay or prevent Alzheimer disease dementia hold the promise of sizable personal and public benefit. The nomenclature, research designs, and interpretation of results for studies assessing prevention outcomes, however, are inconsistent and would benefit from greater consensus about the necessary requirements for specific intervention claims. Moreover, the public space includes substantial media attention, direct-to-consumer diagnostics, and marketing of unproven interventions for brain health and dementia prevention. This article outlines these issues in hopes of catalyzing further consensus building and alerting professional and regulatory agencies to these topics.

Indexed as

Alzheimer DiseaseHumans

Identifiers

PMID42467872
PMCPMC13382872

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.